Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BVS NASDAQ:DRTS NASDAQ:PROF NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$9.28$9.67$5.81▼$11.25$775.20M0.72526,848 shs734,901 shsDRTSAlpha Tau Medical$10.04$8.08$2.81▼$11.62$883.62M1.11963,645 shs856,305 shsPROFProfound Medical$6.83$6.48$3.76▼$8.95$248.19M0.7376,298 shs31,870 shsTNDMTandem Diabetes Care$14.97$19.22$9.98▼$29.65$1.03B1.642.76 million shs1.99 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus0.00%-12.70%-8.03%+6.42%+927,999,900.00%DRTSAlpha Tau Medical0.00%+0.10%+24.10%+35.86%+234.67%PROFProfound Medical0.00%-0.87%-2.29%-4.48%+33.14%TNDMTandem Diabetes Care0.00%+10.64%-26.47%-44.35%-27.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$9.28$9.67$5.81▼$11.25$775.20M0.72526,848 shs734,901 shsDRTSAlpha Tau Medical$10.04$8.08$2.81▼$11.62$883.62M1.11963,645 shs856,305 shsPROFProfound Medical$6.83$6.48$3.76▼$8.95$248.19M0.7376,298 shs31,870 shsTNDMTandem Diabetes Care$14.97$19.22$9.98▼$29.65$1.03B1.642.76 million shs1.99 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus0.00%-12.70%-8.03%+6.42%+927,999,900.00%DRTSAlpha Tau Medical0.00%+0.10%+24.10%+35.86%+234.67%PROFProfound Medical0.00%-0.87%-2.29%-4.48%+33.14%TNDMTandem Diabetes Care0.00%+10.64%-26.47%-44.35%-27.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 3.00Buy$14.0050.86% UpsideDRTSAlpha Tau Medical 2.33Hold$11.5014.54% UpsidePROFProfound Medical 2.00Hold$12.0075.70% UpsideTNDMTandem Diabetes Care 2.52Moderate Buy$29.6397.94% UpsideCurrent Analyst Ratings BreakdownLatest PROF, TNDM, DRTS, and BVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026PROFProfound Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026BVSBioventus Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$14.005/20/2026DRTSAlpha Tau Medical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/19/2026DRTSAlpha Tau Medical Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$5.00 ➝ $8.005/18/2026TNDMTandem Diabetes Care Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$35.00 ➝ $25.005/12/2026DRTSAlpha Tau Medical LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $14.005/12/2026DRTSAlpha Tau Medical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $15.005/11/2026TNDMTandem Diabetes Care BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold5/11/2026TNDMTandem Diabetes Care Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026TNDMTandem Diabetes Care BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$56.00 ➝ $55.005/11/2026TNDMTandem Diabetes Care Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.00 ➝ $31.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$568.09M1.36$1.27 per share7.28$2.80 per share3.31DRTSAlpha Tau MedicalN/AN/AN/AN/A$0.79 per shareN/APROFProfound Medical$16.10M15.42N/AN/A$1.64 per share4.16TNDMTandem Diabetes Care$1.01B1.01N/AN/A$1.93 per share7.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus$22.73M$0.4122.6310.431.184.94%29.97%9.52%N/ADRTSAlpha Tau Medical-$42.63M-$0.67N/AN/AN/AN/A-73.23%-52.90%8/10/2026 (Estimated)PROFProfound Medical-$42.57M-$1.24N/AN/AN/A-206.76%-78.88%-64.06%8/13/2026 (Estimated)TNDMTandem Diabetes Care-$204.71M-$1.40N/AN/AN/A-9.20%-53.88%-7.88%8/5/2026 (Estimated)Latest PROF, TNDM, DRTS, and BVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026DRTSAlpha Tau Medical-$0.13-$0.26-$0.13-$0.26$0.05 millionN/A5/7/2026Q1 2026PROFProfound Medical-$0.24-$0.19+$0.05-$0.19$4.85 million$5.34 million5/7/2026Q1 2026TNDMTandem Diabetes Care-$0.46-$0.30+$0.16-$0.30$240.41 million$247.22 million5/6/2026Q1 2026BVSBioventus$0.09$0.15+$0.06$0.04N/A$132.09 million3/9/2026Q4 2025DRTSAlpha Tau Medical-$0.13-$0.14-$0.01-$0.92$0.06 millionN/A3/5/2026Q4 2025BVSBioventus$0.22$0.24+$0.02$0.21N/A$157.90 million3/5/2026Q4 2025PROFProfound Medical-$0.27-$0.27N/A-$0.27$10.53 million$5.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/ADRTSAlpha Tau MedicalN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.081.691.13DRTSAlpha Tau Medical0.097.797.45PROFProfound MedicalN/A6.565.71TNDMTandem Diabetes Care4.543.583.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%DRTSAlpha Tau Medical2.65%PROFProfound Medical47.86%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipBVSBioventus33.00%DRTSAlpha Tau Medical39.50%PROFProfound Medical1.52%TNDMTandem Diabetes Care2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20083.54 million55.97 millionN/ADRTSAlpha Tau Medical8088.01 million53.25 millionNo DataPROFProfound Medical15036.34 million35.79 millionOptionableTNDMTandem Diabetes Care2,50068.53 million67.09 millionOptionablePROF, TNDM, DRTS, and BVS HeadlinesRecent News About These CompaniesTandem Diabetes Care (TNDM) Is Up 16.7% After Beating Q3 Views And Reaffirming 2025 EBITDA Target – Has The Bull Case Changed?May 24 at 7:05 PM | finance.yahoo.comSilver Economy Investing: Why the Healthcare Giants Are in FocusMay 19, 2026 | zacks.comTandem Diabetes Care (NASDAQ:TNDM) Given New $25.00 Price Target at Bank of AmericaMay 19, 2026 | americanbankingnews.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 16, 2026 | americanbankingnews.comCritical Analysis: Tandem Diabetes Care (NASDAQ:TNDM) & Imris (OTCMKTS:IMRSQ)May 15, 2026 | americanbankingnews.comTandem Diabetes’s Q1 earnings call: Our top 5 analyst questionsMay 14, 2026 | msn.comTNDM stock down following Q1 earnings & revenue beat, gross margin upMay 14, 2026 | msn.comTNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin UpMay 14, 2026 | zacks.comTandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comTandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 12, 2026 | zacks.comTandem Diabetes Care, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comTandem Diabetes Care (NASDAQ:TNDM) Receives "Buy" Rating from Truist FinancialMay 11, 2026 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 11, 2026 | finance.yahoo.comTandem Diabetes Care, Inc. $TNDM Shares Acquired by Vanguard Group Inc.May 11, 2026 | marketbeat.comTandem Diabetes Care (TNDM) Gets a Buy from Piper SandlerMay 10, 2026 | theglobeandmail.comTandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call TranscriptMay 10, 2026 | seekingalpha.comTandem Diabetes Care Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comTandem to submit tubless pump to FDA with Street-beating Q1 on record pump shipmentsMay 8, 2026 | drugdeliverybusiness.comDTandem Diabetes Care Charts Growth Amid TransitionMay 8, 2026 | tipranks.comTandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up After Earnings BeatMay 8, 2026 | marketbeat.comTNDM Q1 deep dive: Margin expansion and pipeline advances amid business model shiftMay 8, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRobinhood, SoFi, and Webull Are Telling Very Different StoriesBy Peter Frank | May 17, 2026Verizon’s Signal Strength: The Turnaround Call Is Loud and ClearBy Jeffrey Neal Johnson | April 30, 2026SanDisk Earnings Crush Estimates With 251% Revenue SurgeBy Ryan Hasson | May 1, 2026AST SpaceMobile Gets FCC Green Light for Direct-to-Device Service After Launch SetbackBy Jessica Mitacek | April 28, 2026Amprius Technologies Ups the Voltage on Forward OutlookBy Thomas Hughes | May 7, 2026PROF, TNDM, DRTS, and BVS Company DescriptionsBioventus NASDAQ:BVS$9.28 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$9.27 -0.01 (-0.11%) As of 05/22/2026 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.Alpha Tau Medical NASDAQ:DRTS$10.04 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$10.20 +0.17 (+1.64%) As of 05/22/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Profound Medical NASDAQ:PROF$6.83 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$6.83 0.00 (0.00%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.Tandem Diabetes Care NASDAQ:TNDM$14.97 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$14.90 -0.07 (-0.47%) As of 05/22/2026 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
